Le Lézard20h
Aileron Therapeutics Announces Rebranding to Rein Therapeutics
Rein Therapeutics ("Rein") , formerly known as Aileron Therapeutics, Inc. ("Aileron") , a biopharmaceutical company advancing a ...
Pharmabiz1d
Quanta receives US FDA clearance to begin phase 1 trial of QTX3544, an oral G12V-preferring, dual ON/OFF state, multi-KRAS inhibitor
Quanta receives US FDA clearance to begin phase 1 trial of QTX3544, an oral G12V-preferring, dual ON/OFF state, multi-KRAS inhibitor: Radnor, Pennsylvania Friday, January 10, 2025 ...
Quanta Announces IND Clearance by U.S. FDA for QTX3544, an Oral G12V-Preferring Multi-KRAS Inhibitor, and Other Pipeline Updates
Additionally, the Phase 1 clinical trial evaluating QTX3034, an oral G12D-preferring multi-KRAS inhibitor, as a monotherapy and in combination with cetuximab, continues to enroll patients, and data is ...
Le Lézard2d
Aspect Biosystems Raises US$115 Million Series B Financing to Advance Bioprinted Tissue Therapeutics
Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics as a new category in regenerative medicine, today announced that it has closed a US$115 million ...
Janux Therapeutics: mCRPC TAM And Promising JANX007's Phase 1 Data
Janux Therapeutics has a robust balance sheet, with $658.1 million in liquid assets and no debt. See why I reiterate my buy ...
High Q Technologies Announces Commercial Availability and First Sale of the FATHOM™ EPR Spectrometer
High Q Technologies today announced the commercial availability and first sale of FATHOM, a class-leading and innovative EPR ...
Business Wire4d
Acellera Therapeutics Unveils AceForce 1.0: A Novel Family of Next-Generation Neural Network Potential Accelerating Drug Discovery
Acellera Therapeutics, a pioneer in computational chemistry and AI-driven drug discovery, today announced the launch of ...
Pharmaceutical Technology5d
QTX-3046 by Quanta Therapeutics for Lung Cancer: Likelihood of Approval
QTX-3046 is under clinical development by Quanta Therapeutics and currently in Phase I for Lung Cancer. According to GlobalData, Phase I drugs for Lung Cancer have a 78% phase tra ...
Dyne Therapeutics (NASDAQ:DYN) Shares Down 3.7% – What’s Next?
Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) traded down 3.7% during trading on Friday . The company traded as low ...
Capricor Therapeutics (NASDAQ:CAPR) Sees Strong Trading Volume – Here’s What Happened
Shares of Capricor Therapeutics Inc (NASDAQ:CAPR – Get Free Report) saw strong trading volume on Friday . 413,080 shares were traded during trading, a decline of 47% from the previous session’s volume ...